Not Signed In -
Vaccine Development |
|
|
Clinical Trial: Development of a New HIV Vaccine
This study is currently recruiting patients.
|
Purpose
The purpose of the study is to determine the safety of a new HIV vaccine and to evaluate the immune response to the vaccine. Only some HIV genes are used to make the vaccine and therefore the vaccine cannot itself cause HIV or AIDS.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| HIV Infections | Vaccine: PolyEnv1 | Phase I |
MedlinePlus related topics: AIDS
Study Type: Interventional
Study Design: Prevention, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety Study
Official Title: Evaluation of the Safety of a Polyvalent Vaccinia Virus HIV-1 Envelope Recombinant Vaccine (PolyEnv1) in Healthy Adults
Expected Total Enrollment: 24
Study start: October 1997
HIV-1 presents several challenges to vaccine design, including: 1) high mutation rates resulting in tremendous diversity of virus envelope, the target of neutralizing antibody, such that antibody elicited to one envelope may not protect from virus with a distinct envelope; 2) envelope from infected persons differs from envelopes obtained from T-cell line cultures, the usual source of envelope for vaccines; and 3) envelope glycoprotein exists as oligomers on the virion surface, not as the monomers used in previous vaccines. This study will test a new vaccine that has been designed to meet these challenges by delivering diverse, patient-derived, oligomeric envelopes to induce multiple type-specific responses capable of recognizing native envelope on natural variants. The vaccine vector used in this vaccine trial is recombinant vaccinia virus based on the NYCDH vaccinia isolate.
Participants in this study will receive the PolyEnv1 HIV vaccine and will be followed for one year. Laboratory tests will be performed at 10 study visits to monitor the participants’ immunologic response and assess the safety of the vaccine. Patients will also have numerous HIV tests throughout the study period.
Eligibility
Ages Eligible for Study: 18 Years - 32 Years, Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
Inclusion Criteria:
- HIV-1 negative
- Availability for one year of follow-up
- No evidence of previous smallpox vaccination
- Acceptable methods of contraception
Exclusion Criteria:
- Immunosuppressive or chronic illness
- Medical or psychological conditions which could affect compliance
- High risk for HIV infection
- Live attenuated vaccines within 60 days
- Experimental agents within 30 days
- Blood products within past 6 months
- Eczema
- Pregnant or lactating women
- Household contact with immunodeficient person, pregnant woman, or child less than 12 months of age
- Allergy to gentamicin
Location and Contact Information
Tennessee
St. Jude Children's Research Hospital, Memphis, Tennessee, 38105, United States; Recruiting
Karen S. Slobod, MD 901-495-3486 karen.slobod@stjude.org
Karen S. Slobod, MD, Principal Investigator
Julia L. Hurwitz, PhD, Principal Investigator
Karen S. Slobod, MD, Principal Investigator, Associate Member
Julia L. Hurwitz, PhD, Principal Investigator, Member
More Information
Click here for more information about St. Jude Children's Research Hospital.
Click here to learn more about HIV vaccines
Publications
Rencher SD, Slobod KS, Dawson DH, Lockey TD, Hurwitz JL. Does the key to a successful HIV type 1 vaccine lie among the envelope sequences of infected individuals? AIDS Res Hum Retroviruses. 1995 Sep;11(9):1131-3. No abstract available.
Rencher SD, Lockey TD, Srinivas RV, Owens RJ, Hurwitz JL. Eliciting HIV-1 envelope-specific antibodies with mixed vaccinia virus recombinants. Vaccine. 1997 Feb;15(3):265-72.
Richmond JF, Mustafa F, Lu S, Santoro JC, Weng J, O'Connell M, Fenyo EM, Hurwitz JL, Montefiori DC, Robinson HL. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Virology. 1997 Apr 14;230(2):265-74.
Caver TE, Lockey TD, Srinivas RV, Webster RG, Hurwitz JL. A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation. Vaccine. 1999 Mar 17;17(11-12):1567-72.
Lockey TD, Slobod KS, Caver TE, D'Costa S, Owens RJ, McClure HM, Compans RW, Hurwitz JL. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees. Immunol Res. 2000;21(1):7-21.
Surman S, Lockey TD, Slobod KS, Jones B, Riberdy JM, White SW, Doherty PC, Hurwitz JL. Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing. Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4587-92. Epub 2001 Apr 03.
Zhan X, Slobod KS, Surman S, Brown SA, Lockey TD, Coleclough C, Doherty PC, Hurwitz JL. Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein. J Virol. 2003 Apr;77(7):4231-6.
Brown SA, Stambas J, Zhan X, Slobod KS, Coleclough C, Zirkel A, Surman S, White SW, Doherty PC, Hurwitz JL. Clustering of Th cell epitopes on exposed regions of HIV envelope despite defects in antibody activity. J Immunol. 2003 Oct 15;171(8):4140-8.
Record last reviewed: March 2005
Last Updated: March 2, 2005
Record first received: January 17, 2003
ClinicalTrials.gov Identifier: NCT00051922
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
